MiMedx Group

MDXG

Market cap $724M

MiMedx (MDXG) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA 1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2025.

MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

Agreement expands offering to include additional sheet, particulate and flowable products Agreement expands offering to include additional sheet, particulate and flowable products

Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications

MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.

From a technical perspective, MiMedx Group, Inc (MDXG) is looking like an interesting pick, as it just reached a key level of support. MDXG's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16 th Annual Alpha Select Conference | New York, NY Tuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NY Thursday, November 20, 20251:1 sessions Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum or Canaccord representative.